Therapeutic Response

Wild type ALK and Wild type EGFR status confers therapeutic sensitivity to Carboplatin in combination with Nivolumab and Paclitaxel in patients with Non-Small Cell Lung Cancer.

Statements

Source and description

Opdivo (nivolumab) [package insert]. FDA. The U.S. Food and Drug Administration granted approval to nivolumab in combination with platinum-doublet chemotherapy for the neoadjuvant treatment, followed by single-agent nivolumab as adjuvant treatment after surgery, of adult patients with resectable (tumors >= 4 cm or node positive) non-small cell lung cancer and no known EGFR mutations or ALK rearrangements. This indication is based on CHECKMATE-816 (NCT02998528), a randomized, open label trial where patients received either: carboplatin with paclitaxel for either histology, cisplatin with pemetrexed for non-squamous histology, or cisplatin with gemcitabine for squamous histology.